Nature Communications (Jan 2020)
Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties
- Yuya Terashima,
- Etsuko Toda,
- Meiji Itakura,
- Mikiya Otsuji,
- Sosuke Yoshinaga,
- Kazuhiro Okumura,
- Francis H. W. Shand,
- Yoshihiro Komohara,
- Mitsuhiro Takeda,
- Kana Kokubo,
- Ming-Chen Chen,
- Sana Yokoi,
- Hirofumi Rokutan,
- Yutaka Kofuku,
- Koji Ohnishi,
- Miki Ohira,
- Toshihiko Iizasa,
- Hirofumi Nakano,
- Takayoshi Okabe,
- Hirotatsu Kojima,
- Akira Shimizu,
- Shiro Kanegasaki,
- Ming-Rong Zhang,
- Ichio Shimada,
- Hiroki Nagase,
- Hiroaki Terasawa,
- Kouji Matsushima
Affiliations
- Yuya Terashima
- Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences (RIBS), Tokyo University of Science
- Etsuko Toda
- Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences (RIBS), Tokyo University of Science
- Meiji Itakura
- Department of Thoracic Disease, Chiba Cancer Center
- Mikiya Otsuji
- Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo
- Sosuke Yoshinaga
- Department of Structural BioImaging, Faculty of Life Sciences, Kumamoto University
- Kazuhiro Okumura
- Chiba Cancer Center Research Institute
- Francis H. W. Shand
- Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo
- Yoshihiro Komohara
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
- Mitsuhiro Takeda
- Department of Structural BioImaging, Faculty of Life Sciences, Kumamoto University
- Kana Kokubo
- Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences (RIBS), Tokyo University of Science
- Ming-Chen Chen
- Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences (RIBS), Tokyo University of Science
- Sana Yokoi
- Chiba Cancer Center Research Institute
- Hirofumi Rokutan
- Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo
- Yutaka Kofuku
- Graduate School of Pharmaceutical Sciences, The University of Tokyo
- Koji Ohnishi
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
- Miki Ohira
- Chiba Cancer Center Research Institute
- Toshihiko Iizasa
- Department of Thoracic Disease, Chiba Cancer Center
- Hirofumi Nakano
- Drug Discovery Initiative, The University of Tokyo
- Takayoshi Okabe
- Drug Discovery Initiative, The University of Tokyo
- Hirotatsu Kojima
- Drug Discovery Initiative, The University of Tokyo
- Akira Shimizu
- Department of Analytic Human Pathology, Nippon Medical School
- Shiro Kanegasaki
- Research Institute, National Center for Global Health and Medicine
- Ming-Rong Zhang
- Department of Radiopharmaceutics Development, National Institutes for Quantum and Radiological Science and Technology
- Ichio Shimada
- Graduate School of Pharmaceutical Sciences, The University of Tokyo
- Hiroki Nagase
- Chiba Cancer Center Research Institute
- Hiroaki Terasawa
- Department of Structural BioImaging, Faculty of Life Sciences, Kumamoto University
- Kouji Matsushima
- Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences (RIBS), Tokyo University of Science
- DOI
- https://doi.org/10.1038/s41467-020-14338-5
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 16
Abstract
The cytoplasmic protein FROUNT can bind to chemokine receptors and enhance chemokine signalling. Here, the authors show that inhibiting FROUNT in macrophages either by knockdown of the gene or using the anti-alcoholism drug disulfiram, results in a reduction in tumour growth.
